Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2016–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Market Cap | $163525 | $17M | — | — | — | — | — |
| Enterprise Value | $641525 | $17M | — | — | — | — | — |
| P/E Ratio → | -0.02 | — | — | — | — | — | — |
| P/S Ratio | 0.89 | 91.93 | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 94.54 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | -380.7% | -1697.3% | 30.7% | -1.7% |
| Operating Margin | -5421.3% | -5421.3% | -9627.9% | -822.3% | -3120.2% | -561.4% | 319.1% |
| Net Profit Margin | -3951.9% | -3951.9% | -9595.1% | -848.4% | -3069.8% | -561.4% | -327.2% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -479.8% | — | — |
| ROA | -180.4% | -180.4% | -154.0% | -174.4% | -117.7% | -99.5% | -71.7% |
| ROIC | — | — | — | — | — | — | — |
| ROCE | — | — | — | -757.4% | -166.9% | -121.6% | 92.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.18 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -1.95 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | -1.30 |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -25.64 | -25.64 | -510.70 | -67.28 | -881.00 | — | 77.91 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.19 | 0.19 | 0.15 | 0.89 | 1.53 | 5.71 | 3.84 |
| Quick Ratio | 0.19 | 0.19 | 0.15 | 0.89 | 1.53 | 5.71 | 3.84 |
| Cash Ratio | 0.15 | 0.15 | 0.06 | 0.67 | 1.47 | 5.54 | 3.75 |
| Asset Turnover | — | 0.04 | 0.04 | 0.17 | 0.06 | 0.13 | 0.22 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 644.24 | 263.28 | 365.18 | 30.42 | 30.51 | 23.39 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $313267 | $311900 | $310400 | $309133 | $392200 | $387933 |
Imminent liquidity insolvency risk
Based on reported figures, Abpro's P/S ratio of 0.89 suggests the market is heavily discounting the company's intellectual property, likely pricing in a high probability of insolvency or extreme dilution rather than the potential long-term value of the DiversImmune platform compared to better-capitalized peers like Xencor.
The current valuation multiple appears to reflect a market that has largely abandoned the company's growth narrative in favor of a liquidation-risk assessment. Investors should monitor whether this discount persists, as it suggests that the market views the company's pipeline as insufficient to justify a premium valuation relative to its peers.
As reported in financial statements, Abpro's current ratio has deteriorated to a precarious 0.07 as of 2025Q3, indicating that the company lacks the liquid assets necessary to cover its immediate short-term obligations, thereby heightening the risk of a near-term liquidity crisis for the biotechnology firm.
The rapid decline in the current ratio from 0.19 in 2024Q4 to 0.07 in 2025Q3 underscores a severe inability to manage short-term liabilities. This trend suggests that the company may be forced into emergency financing or restructuring, as the current cash position is insufficient to sustain ongoing clinical trial operations.
According to recent SEC filings, Abpro exhibits highly volatile working capital trends, with DPO figures reaching 12,229 days in 2025Q3, which suggests that the company is significantly delaying payments to vendors to preserve its dwindling cash reserves during critical clinical development phases.
The extreme DPO levels indicate that the company is likely operating under severe supplier pressure or has reached the limits of its credit terms. This reliance on extended payment cycles is a classic indicator of a firm struggling to manage its cash conversion cycle while awaiting milestone-based revenue.
As indicated by the company's financial data, the P/S ratio is a fundamentally flawed metric for Abpro, as it obscures the lack of recurring revenue and the binary nature of milestone-based income, which should instead be evaluated through a probability-weighted net present value of the clinical pipeline.
Using standard revenue multiples for a pre-commercial biotech like Abpro ignores the fact that current inflows are non-recurring and do not represent a sustainable business model. Analysts should focus on the cash runway and the probability of success for ABP-100 rather than traditional valuation multiples that assume a stable revenue base.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABP stock.
Abpro Corporation's current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, Abpro Corporation is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Abpro Corporation has 100.0% gross margin and -5421.3% operating margin.